Patient with Parkinson‘s disease in data sources of the National Health Information System
Authors:
J. Búřil 1; P. Búřilová 2,3; A. Pokorná 2,3; I. Kováčová 3; M. Baláž 1
Authors place of work:
I. neurologická klinika, LF MU a FN u sv. Anny v Brně
1; Katedra ošetřovatelství a porodní, asistence, LF MU, Brno
2; Ústav zdravotnických informací, a statistiky ČR, Praha
3
Published in the journal:
Cesk Slov Neurol N 2020; 83/116(5): 550-554
Category:
Original Paper
doi:
https://doi.org/10.14735/amcsnn2020550
Summary
Aim: Parkinson’s disease (PD) is a neurodegenerative disease manifested by the triad of hypokinetic-rigid syndrome, postural instability and resting tremor. As a consequence of the aging of population, the incidence and prevalence of PD are increasing, and as the disease progresses, motor and autonomic symptoms and neuropsychiatric complications are increasing. Demographic description of the population in order to evaluate the reported hospitalization reasons and possible co-morbidities in a selected group of patients with the main diagnoses according to the International Classification of Diseases (ICD-10): G20 (Parkinson’s disease), G23.1, G23.2, G23.3 (Other degenerative diseases of basal ganglia) and G31.8 (Other specified degenerative diseases of the nervous system) was the aim of this study.
Methods: Retrospective data analysis using data from the National Health Information System (NZIS) and the National Register of Reimbursed Health Services (NRHZS). Analysis of epidemiological data to determine hospitalization reasons and possible co-morbidities in a selected group of patients with established diagnoses.
Results: A total of 78,453 cases were identified from the national registers in 2012–2018. From all hospitalizations of patients with follow-up diagnoses, the majority (58.1%) in 2017 were due to their main neurological diagnosis. From the other recurrent hospital admissions diagnosed upon admission, the most common were Other urinary tract diseases (N39) in 2.1% of patients. In 2012–2018, 39.5% of patients (N = 30,974) died because of the main follow-up diagnoses and, coronary heart disease was the most frequently reported cause of death in PD patients (20.4%).
Conclusion: According to available data from the NZIS register, hospitalization reasons and causes of death reported according to ICD-10 in patients with Parkinson’s disease were identified. In 2017, most (58.1%) patients were admitted with a major neurological diagnosis. The most frequently reported cause of death between 2012 and 2018 in patients with PD was coronary heart disease (20.4%).
Keywords:
mortality – incidence – prevalence – Parkinson‘s disease – atypical parkinsonian syndromes
Zdroje
1. Gil-Prieto R, Pascual-Garcia R, San-Roman-Montero J et al. Measuring the burden ofhospitalization in patients with Parkinson’s Disease in Spain. PLoS ONE 2016; 11 (3): e0151563. doi: 10.1371/journal.pone.0151563.
2. Hirsch L, Jette N, Frolkis A et al. The incidence of Parkinson‘s disease: a systematic review and meta-analysis. Neuroepidemiology 2016; 46 (4): 292–300. doi: 10.1159/000445751.
3. Dodel RC, Singer M, Köhne-Volland R et al. The economic impact of Parkinson‘s disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14 (3): 299–312. doi: 10.2165/00019053-199814030-00006.
4. GBD. Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson‘s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17 (11): 939–953. doi: 10.1016/S1474-4422 (18) 30295-3.
5. Leibson CL, Maraganore DM, Bower JH et al. Comorbid conditions associated with Parkinson‘s disease: a population-based study. Mov Disord 2006; 21 (4): 446–455. doi: 10.1002/mds.20685.
6. Kis B, Schrag A, Ben-Shlomo Y. Novel three-stage ascertainment method Prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology 2002; 58 (12): 1820–1825. doi: 10.1212/wnl.58.12.1820.
7. Riedel O, Klotsche J, Wittchen HU et al. Motor impairment, depression, dementia: which forms the impression of disease severity in Parkinson‘s disease? Parkinsonism Relat Disord 2014; 20 (12): 1365–1370. doi: 10.1016/j.parkreldis.2014.09.025.
8. Keranen T, Kaakkola S, Sotaniemi K. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9 (3): 163–168. doi: 10.1016/s1353-8020 (02) 00097-4.
9. Spottke AE, Reuter M, Machat O. Cost of illness and its predictors for Parkinson‘s disease in Germany. PharmacoEconomics 2005; 23 (8): 817–836. doi: 10.2165/00019053-200523080-00007.
10. Vossius C, Nilsen OB, Larsen JP. Parkinson‘s disease and hospital admissions: frequencies, diagnoses and costs. Acta Neurol Scand 2010; 121 (1): 38–43. doi: 10.1111/j.1600-0404.2009.01239.x.
11. Shahgholi L, De Jesus S, Wu SS. Hospitalization and rehospitalization in Parkinson disease patients: data from the National Parkinson Foundation Centers of Excellence. PLoS One 2017; 12 (7): e0180425. doi: 10.1371/journal.pone.0180425.
12. Huang YP, Chen LS, Yen MF. Parkinson‘s disease is related to an increased risk of ischemic stroke-a population-based propensity score-matched follow-up study. PLoS One 2013; 8 (9): e68314. doi: 10.1371/journal.pone.0068314.
13. Braga M, Pederzoli M, Antonini A et al. Reasons for hospitalization in Parkinson‘s disease: A case-control study. Parkinsonism Relat Disord 2014; 20 (5): 488–492. doi: 10.1016/j.parkreldis.2014.01.022.
14. Huang YF, Yeh CC, Chou YC et al. Stroke in Parkinson’s disease. QJM 2019; 112 (4): 269–274. doi: 10.1093/ qjmed/hcz015.
15. Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson‘s disease. Mov Disord 2005; 20 (9): 1104–1108. doi: 10.1002/mds.20485.
16. Guttman M, Slaughter PM, Theriault ME et al. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 2004; 19 (1): 49–53. doi: 10.1002/mds.10648.
17. McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson‘s disease: prevalence, aetiology and management. Parkinsonism Relat Disord 2017; 35: 8–16. doi: 10.1016/j.parkreldis.2016.10.024.
18. Winge K, Nielsen KK. Bladder dysfunction in advanced Parkinson‘s disease. Neurourol Urodyn 2012; 31 (8): 1279–1283. doi: 10.1002/nau.22237.
19. Sakakibara R, Panicker J, Finazzi-Agro E et al. A guideline for the management of bladder dysfunction in Parkinson‘s disease and other gait disorders. Neurourol Urodynam 2016; 35 (5): 551–563. doi: 10.1002/nau.22764.
20. Gil-Prieto R, Pascual-Garcia R, San-Roman-Montero J et al. Measuring the burden of hospitalization in patients with Parkinson’s disease in Spain. PLoS One 2016; 11 (3): e0151563. doi: 10.1371/journal.pone.0151563.
21. Fall PA, Saleh A, Fredrickson M et al. Survival time, mortality, and cause of death in elderly patients with Parkinson‘s disease. A 9-year follow-up. Mov Disord 2003; 18 (11): 1312–1316. doi: 10.1002/mds.10537.
22. Auffret M, Morel V, Robert G et al. Modes of death of hospitalized patients with Parkinson’s disease: a 12-yearretrospective analysis (P2.6-051). Neurology 2019; 92 (15 Suppl): P2.6-051.
23. Taeyeop L, Hochang BL, Ahn MH et al. Increased suicide risk and clinical correlates of suicide among patients with Parkinson‘s disease. Parkinsonism Relat Disord 2016; 32: 102–107. doi: 10.1016/j.parkreldis.2016.09.006.
24. Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 2001; 14 (3): 120–124. doi: 10.1177/089198870101400304.
25. Gerlach OH, Broen MP, van Domburg PH et al. Deterioration of Parkinson‘s disease during hospitalization: survey of 684 patients. BMC Neurol 2012; 12 (1): 13. doi: 10.1186/1471-2377-12-13.
Štítky
Paediatric neurology Neurosurgery NeurologyČlánok vyšiel v časopise
Czech and Slovak Neurology and Neurosurgery
2020 Číslo 5
- Memantine Eases Daily Life for Patients and Caregivers
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
Najčítanejšie v tomto čísle
- Diffuse low grade gliomas
- Respiratory rehabilitation in patients with amyotrophic lateral sclerosis
- Amnesia Light and Brief Assessment (ALBA) test – the second version and repeated examinations
- Neurorehabilitation in patients with amyotrophic lateral sclerosis